FDA accepts supplemental biologics license application for Xolair (omalizumab) for the treatment of nasal polyps

Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to intranasal corticosteroids.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news